ClinicalTrials.Veeva

Menu
G

Genesis Clinical Research | Tampa, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

MK-2060
PF-07817883
PF-07081532
PF-07321332
PF-07923568
Ritonavir
Dapagliflozin
nalbuphine HCl
SYNB8802
Sevelamer hydrochloride

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 58 total trials

A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)

Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (L...

Enrolling
Renal Impairment
Healthy
Drug: Enlicitide

The primary purpose of this open-label study is to characterize the plasma pharmacokinetics (PK) of manogepix (active moiety of fosmanogepix) in part...

Enrolling
Hepatic Impairment
Drug: Fosmanogepix

This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (P...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: RTA 901
Drug: RTA 901-Matching Placebo

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The purpose of this study is to characterize the single-dose pharmacokinetic (PK) of apalutamide in participants with severe hepatic impairment relat...

Enrolling
Hepatic Impairment
Drug: Apalutamide

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and...

Enrolling
Chronic Kidney Diseases
Type 2 Diabetes Mellitus
Biological: Renal Autologous Cell Therapy (REACT)
Procedure: Sham Comparator

The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial....

Enrolling
Primary Membranous Nephropathy
Drug: SNP-ACTH (1-39) Gel
Drug: Rituximab

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Other: Placebo
Drug: Deucravacitinib

The purpose of the study is to learn about:* how PF-07817883 is processed in the body of adult participants.* the safety of PF-07817883.These partici...

Enrolling
COVID-19
Drug: PF-07817883

The purpose of this study is to understand how Osivelotor is processed in people with loss of liver function.This study is seeking participants that...

Enrolling
Liver Diseases
Drug: Osivelotor

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end s...

Active, not recruiting
End-Stage Renal Disease
End-Stage Kidney Disease
Drug: MK-2060
Drug: Placebo

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Enrolling
Proteinuric Kidney Disease
Drug: Placebo
Drug: VX-147

This is a multicenter, open-label, non-randomized, parallel-group, single-dose, 2-part, adaptive study in which up to approximately 32 adult subjects...

Active, not recruiting
Hyperuricemia
Gout
Drug: SAP-001

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers...

Active, not recruiting
IgA Nephropathy
Drug: BION-1301 Multiple Doses
Drug: Placebo Multiple Doses

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Primary Objective:Primary population (former smokers cohort):* Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of ac...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

Trial sponsors

Pfizer logo
Merck Sharp & Dohme (MSD) logo
Amgen logo
Vertex Pharmaceuticals logo
Bristol-Myers Squibb (BMS) logo
Gilead Sciences logo
T
A
Abbott logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems